ArticleCureus2025
Amyloidosis-Related Cardiomyopathy Revealing Waldenstrom Macroglobulinemia: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac amyloidosis is a rare infiltrative disease caused by the deposition of extracellular insoluble aggregates of misfolded proteins. Most cardiac amyloidosis seen in the clinic is due to either amyloid light-chain (AL) of immunoglobulins or transthyretin accumulation in various cardiac structures. AL amyloidosis is most often secondary to a monoclonal gammopathy of undetermined significance (MGUS) or multiple myeloma. More rarely, it is associated with lymphoplasmacytic lymphoma, a low-grade, mature, B-cell non-Hodgkin lymphoma. Here, we present a rare case of cardiac AL amyloidosis caused by Waldenstrom macroglobulinemia in a 70-year-old man. The clinical and biological characteristics of the patient, as well as the mutational profile, are detailed and discussed. This case report sheds light on the rare association of AL amyloidosis and Waldenstrom macroglobulinemia. It underlines the importance of the multidisciplinary collaboration between cardiologists, hematologists, clinical pathologists, and amyloidosis specialists to overcome diagnostic challenges using specific key tools encompassing immunofixation electrophoresis, mass spectrometry, immunophenotyping, cardiac magnetic resonance imaging, and next-generation sequencing. All of the above lead to the establishment of an early and appropriate diagnosis of such a rare clinical association, thus optimizing patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.